Zoloft vs. Prozac: Differences, Side Effects, and How to Choose

Zoloft (sertraline) and Prozac (fluoxetine) are two of the most widely prescribed antidepressants in the United States.

Both are selective serotonin reuptake inhibitors (SSRIs), which means they work through the same basic mechanism. But they differ in meaningful ways: their FDA-approved uses, half-lives, side effect profiles, and how they interact with other medications. If you're weighing these two options, understanding those differences can help you have a more productive conversation with your provider.

Neither medication is universally superior. The right choice depends on your specific diagnosis, medical history, other medications you take, and how your body responds to each drug.

Key Takeaways

• Zoloft and Prozac are both SSRIs with overlapping but distinct FDA-approved uses; Zoloft has approval for more anxiety-related conditions, including PTSD, social anxiety disorder (SAD), OCD, and panic disorder (PD), while Prozac is approved for bulimia nervosa, OCD, PD, and treatment-resistant depression (in combination with olanzapine). Both are approved to treat major depression.

• Prozac's much longer half-life (1–3 days, vs. ~26 hours for Zoloft) means it clears the body slowly. This is helpful if you miss doses, but it also takes longer to discontinue if you need to stop or change medications.

• The best antidepressant is the one that works for your specific situation. A board-certified provider can evaluate your symptoms and history to recommend the most appropriate starting point.

What are SSRIs?

SSRIs are the most commonly prescribed class of antidepressants. They work by blocking the reabsorption (reuptake) of serotonin in the brain, leaving more serotonin available between nerve cells. Over time, the increased serotonin modulates the serotonergic receptors, improving mood, anxiety, sleep, and appetite, among other functions.

According to the National Institute of Mental Health, SSRIs are generally well-tolerated and are typically a first-line treatment for depression and anxiety disorders. Both antidepressants have been studied extensively since getting FDA approvals — Prozac (fluoxetine) in 1987 and Zoloft (sertraline) in 1991 — giving providers decades of real-world data on their safety and effectiveness.

FDA-Approved Uses: Where They Overlap and Differ

Both medications are approved for major depressive disorder, obsessive-compulsive disorder, premenstrual dysphoric disorder (PMDD), and panic disorder. Beyond these, Zoloft and Prozac are approved for distinct conditions.

If you're dealing with PTSD or social anxiety, Zoloft's specific approvals give it an evidence advantage. For bulimia nervosa or treatment-resistant depression, Prozac may be a more suitable choice. 

Prozac is also FDA-approved for pediatric use to treat MDD and OCD in children over 7 years, while Zoloft is FDA-approved to treat OCD in children over 6 years.

Dosing: What to Expect

Both medications are started at lower doses and titrated up based on response and tolerability. Here's a general overview of typical dosing ranges:

Note: Any dosing information is for general understanding purposes only and not meant to be taken as a prescription. Your provider will determine the appropriate dose based on your diagnosis, age, and response to the medication. Many people start at a lower dose to minimize side effects during the adjustment period. Some patients, especially those with anxiety, may start fluoxetine at lower doses (e.g., 10 mg) to improve tolerability.

How They Work in the Body

Half-Life: A Key Difference

One of the most clinically significant distinctions between these two medications is their half-life, which is how long it takes the body to eliminate half of the drug. According to the FDA prescribing information, Prozac (fluoxetine) has an exceptionally long half-life (1-3 days after acute administration and 4-6 days after chronic administration), and its active metabolite (norfluoxetine) remains active for even longer — sometimes up to a week or more.

Sertraline (Zoloft) has a half-life of approximately 26 hours. This shorter half-life has practical implications:

• Missed doses: Prozac's long half-life means blood levels remain stable even if you occasionally miss a dose. With Zoloft, consistency matters more.

• Discontinuation: Stopping Prozac abruptly is less likely to cause discontinuation syndrome (dizziness, flu-like symptoms, irritability) because the levels come down gradually. Zoloft users who stop abruptly are more susceptible to withdrawal symptoms.

• Switching medications: Zoloft clears faster, which can simplify some medication switches, while Prozac’s long half-life is associated with fewer withdrawal symptoms and is sometimes used strategically when discontinuing or switching shorter-acting antidepressants.

• Drug accumulation: Prozac and its active metabolite accumulate over several weeks, meaning it takes longer to reach steady-state levels and to fully clear after stopping.

Comparing Side Effects

Both Zoloft and Prozac share a common side effect profile. The most frequently reported effects include nausea (especially when starting), diarrhea, insomnia or drowsiness, dry mouth, and sexual side effects. Here's how the two compare on specific dimensions based on data from clinical trials:

Drug Interactions: An Important Difference

Both SSRIs can interact with other medications, but Prozac (fluoxetine) is a notably stronger inhibitor of certain liver enzymes, particularly CYP2D6, which affects how other medications are metabolized in the body. A slower metabolism can increase the blood levels of certain medications, such as antipsychotics, antiarrhythmics, beta blockers, and tricyclic antidepressants. In such cases, additional monitoring and dose management may be required.

Zoloft (sertraline) has a much weaker and dose-dependent inhibition of CYP2D6, making it generally preferred when someone is taking multiple medications. 

Both medications carry a risk of serotonin syndrome when combined with other serotonin-affecting drugs (such as MAOIs, triptans, or tramadol) or herbal supplements such as St. John’s wort, and both increase bleeding risk when combined with NSAIDs or blood thinners such as warfarin. Among SSRIs, Prozac (fluoxetine) has a slightly higher risk of drug interactions with warfarin. Neither SSRI should be started within 14 days of stopping an MAOI.

Pregnancy and Breastfeeding

This is an important consideration that is often underaddressed. Untreated depression and anxiety during pregnancy carry their own significant risks. The decision to take or discontinue an antidepressant during pregnancy should be made collaboratively with your OB and psychiatric provider.

Prescribing information for both Zoloft and Prozac indicates a slightly higher risk of persistent pulmonary hypertension (PPHN) and withdrawal in the newborn associated with antidepressant use in the third trimester.

A review published in the Drugs and Lactation Database notes that low levels of Zoloft (sertraline) pass through breastmilk to babies, which is also supported by the FDA prescribing information for Zoloft. Whereas, research cited in the FDA prescribing information reports the presence of Prozac (fluoxetine) and its active metabolite in breastmilk and instances of agitation, irritability, and poor feeding among babies exposed to the medication. 

Since there is more data supporting its relative safety during pregnancy and breastfeeding, Zoloft is often the preferred SSRI in this context. However, each situation is individual — what matters most is a careful weighing of the risks of medication against the risks of untreated illness.

Effectiveness: What Does the Research Show?

Neither medication has been definitively shown to be more effective than the other in head-to-head trials. A large meta-analysis from 2018 published in The Lancet comparing 21 antidepressants found that sertraline (Zoloft) had one of the more favorable balances of effectiveness and tolerability for the treatment of MDD across the class. Fluoxetine (Prozac), although better tolerated by comparison, was not in the more efficacious group. 

However, another Lancet meta-analysis comparing the effectiveness of antidepressants for treating MDD in children and adolescents found only fluoxetine (Prozac) to be significantly more effective than placebo. Fluoxetine also fared better than other antidepressants in terms of tolerability. The antidepressants compared in the study also included sertraline (Zoloft) and escitalopram (Lexapro), among others. 

However, a more recently published commentary in the Journal of Clinical Epidemiology seems to suggest that fluoxetine (Prozac) is no longer a more clinically effective treatment compared to placebo in the treatment of pediatric MDD. This finding is yet to be acknowledged in treatment recommendations from major medical organizations.

Antidepressant response is highly individual — genetics, the specific condition being treated, and other factors all influence outcomes. Which One is Right for You?

Providers consider several factors when choosing between Zoloft and Prozac:

• Diagnosis: Some conditions have stronger evidence for one medication (e.g., Zoloft for PTSD, Prozac for bulimia).

• Other medications: Prozac's stronger enzyme inhibition makes Zoloft preferable in people on multiple drugs.

• History with antidepressants: If you've tried one SSRI before, your provider may prefer starting with a different one.

• Pregnancy or breastfeeding: Zoloft is often preferred based on available safety data.

• Side effect concerns: If activation/insomnia is a concern, Zoloft may be gentler. If discontinuation syndrome is a concern, Prozac's long half-life offers protection.

• Cost: Both are available as low-cost generics and are similarly priced in most pharmacies.

Get Help Choosing the Right Antidepressant For You

Choosing the right antidepressant requires an individualistic approach that takes into account your diagnosis, medical history, past responses to other medications, and side effects, which vary in severity and type from one person to another. Receiving treatment from qualified healthcare providers can make all the difference in treating and managing your condition.

Blossom Health connects you with online psychiatric providers who specialize in helping patients with depression find the right treatment approach, from first-line medications to advanced strategies for treatment-resistant cases. Our providers can guide you through the process with regular follow-up and ongoing medication management.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

Sources

1. National Institute of Mental Health. (2023, December). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications 

2. U.S. Food and Drug Administration. (2023). Zoloft (sertraline) tablets and oral solution: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019839s108,20990s062lbl.pdf 

3. U.S. Food and Drug Administration. (2023). Prozac (fluoxetine) capsules: Prescribing information (NDA 018936, s112). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018936%20s112lbl.pdf 

4. Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C. (1998). Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. Journal of clinical psychopharmacology, 18(3), 193–197.                                          https://pubmed.ncbi.nlm.nih.gov/9617977/ 

5. Harvard Health Publishing. (2022, May 15). Going off antidepressants. https://www.health.harvard.edu/diseases-and-conditions/going-off-antidepressants 

6. Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459223/ 

7. Sproule, B. A., Otton, S. V., Cheung, S. W., Zhong, X. H., Romach, M. K., & Sellers, E. M. (1997). CYP2D6 inhibition in patients treated with sertraline. Journal of clinical psychopharmacology, 17(2), 102–106. https://pubmed.ncbi.nlm.nih.gov/10950472/ 

8. Mayo Clinic Staff. (2024, September 12). Serotonin syndrome: Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758

9. Spina, E., Barbieri, M. A., Cicala, G., Bruno, A., & de Leon, J. (2020). Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert opinion on drug metabolism & toxicology, 16(1), 31–44. https://pubmed.ncbi.nlm.nih.gov/31795773/ 

10. Sertraline. (2026). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development. https://pubmed.ncbi.nlm.nih.gov/30000250/ 

11. Singh HK, Saadabadi A. Sertraline. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547689/ 

12. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366.  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext 

13. Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., … Xie, P. (2016). Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. The Lancet, 388(10047), 881–890. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30385-3/abstract 

14. Ploderl, M., Lyus, R., Horowitz, M. A., Moncrieff, J. (2026).The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatments. Journal of Clinical Epidemiology, 189, 112016 https://www.sciencedirect.com/science/article/pii/S089543562500349X 

15. Mayo Clinic Staff. (2025, August 1). Sertraline (oral route): Description and brand names. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/sertraline-oral-route/description/drg-20065940

16. Mayo Clinic Staff. (2026, April 1). Fluoxetine (oral route): Description and brand names. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/fluoxetine-oral-route/description/drg-20063952 

17. APA – Practice Guideline for Major Depressive Disorder. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424865

18. FDA – Antidepressant Use in Pregnancy. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/antidepressant-use-pregnancy

19. Cleveland Clinic. (n.d.). Sertraline tablets: Uses & side effects. https://my.clevelandclinic.org/health/drugs/18181-sertraline-tablets